Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimavanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 20/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | APLNR | P35414 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503797 | 1.00 | HTR2A (1.00) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL20794857 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL971246 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL20766842 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL971607 | 0.96 | HTR2A (0.93) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Succinic Acid SCHEMBL28763260 | 0.96 | HTR2A (0.91) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL970683 | 0.96 | HTR2A (0.91) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL1395694 | 0.95 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL969828 | 0.95 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL969826 | 0.95 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1908 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743069-A1 | STABLE SOLID DISPERSIONS OF SALCAPROZATE WITH VARIOUS ACTIVE PHARMACEUTICAL INGREDIENTS | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2026-05-20 | — | — | EP | claimed |
| CN-116635014-B | Preparation method of pimavanserin solid preparation | 南京凯旺药业有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4709372-A1 | SMALL MOLECULE INHIBITORS OF GLUTAMINASE | Leal Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12558327-B2 | Methods and compositions for treating sleep apnea | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20260027178-A1 | Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists | REGENERON PHARMA (US) | 2026-01-29 | — | — | US | claimed |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | TERRAN BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | claimed |
| WO-2007124136-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | claimed |
| EP-1794125-A1 | SALTS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND THEIR PREPARATION | Acadia Pharmaceuticals Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| EP-1794126-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| US-20060205780-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | THYGESEN MIKKEL B | 2006-09-14 | — | — | US | claimed |
| US-20060111399-A1 | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation | ACADIA PHARMACEUTICALS INC. | 2006-05-25 | — | — | US | claimed |
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS INC. | 2006-05-18 | — | — | US | claimed |
| WO-2006036874-A1 | SALTS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND THEIR PREPARATION | ACADIA PHARMACEUTICALS INC. (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2006037043-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2006-04-06 | — | — | WO | claimed |
| EP-1589974-A2 | USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE | Acadia Pharmaceuticals Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| WO-2004064753-A2 | USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE | ACADIA PHARMACEUTICALS INC (US) | 2004-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | KRAS, NRAS, HRAS | HTR2A 4070/4885HTR2C 3913/4885ABCB11 2654/4885 |
| US-20060111399-A1 | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation | FH, CPS1, CS | HTR2A 4702/4885HTR2C 4564/4885ABCB11 3806/4885 |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | HTR2A 69/4885HTR2C 83/4885ABCB11 402/4885 |
| US-12558327-B2 | Methods and compositions for treating sleep apnea | ADRA2A, HTR2A, ADRA2B | HTR2A 2/4885HTR2C 14/4885ABCB11 822/4885 |
| US-20060205780-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | MTAP, CPN1, DNPEP | HTR2A 2053/4885HTR2C 1856/4885ABCB11 3919/4885 |
| US-20260027178-A1 | Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists | PARK7, SNCA, LRRK2 | HTR2A 453/4885HTR2C 830/4885ABCB11 4665/4885 |
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | MTAP, CPN1, DNPEP | HTR2A 2053/4885HTR2C 1856/4885ABCB11 3919/4885 |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | DRD2, HTR1D, DRD1 | HTR2A 7/4885HTR2C 4/4885ABCB11 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.